stockrow
Saturday 7 November 2026
Export SPRY’s income statement to Excel — free account
ARS Pharmaceuticals, Inc.
SPRY Healthcare Biotechnology
ARS Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $84.3 million, down 5.46% from fiscal 2024.
- Revenue
- +16.0%
- EPS
- +30.8%
- Free cash flow
- +36.5%
- Total debt
- +138.5%
Quarter to September 2026, against a year earlier
2.79
0.14
+5.28%
Follow SPRY
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
— | 1 | — | — |
+8 more TTM periods Free account |
| 0.00% | (210.37%) | (136.47%) | (92.38%) | ||
| 0.00% | (76.54%) | (64.42%) | (50.50%) | ||
ROIC |
0.00% | (335.65%) | (401.19%) | (296.82%) | |
Return on Tangible Assets |
0.00% | (141.07%) | (100.08%) | (69.05%) | |
Average Days of Receivables |
157.66 | 146.21 | 105.69 | 109.78 | |
Free Cash Flow per Share |
(1.84) | (1.98) | (1.76) | (1.89) | |
Free Cash Flow |
(183.07) | (196.40) | (175.07) | (186.56) | |
Capital Expenditures |
— | — | — | (15.70) | |
| Other line items | |||||
Cash ROIC |
(144.84%) | (59.89%) | (40.39%) | (35.35%) | |
Accounts Receivable Turnover |
2.74 | 3.25 | 5.21 | 5.03 | |
Accounts Payable Turnover |
0.00 | 0.64 | 0.68 | 0.67 | |
Inventory Turnover |
— | 3.28 | 3.18 | 3.01 | |
Average Days of Payables |
0.00 | 651.26 | 687.72 | 678.21 | |
Days of Inventory on Hand |
— | 127.45 | 125.64 | 149.57 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
25.17% | 13.02% | 14.71% | 15.64% | |
Selling, General and Administrative Expense of Revenue |
207.36% | 243.30% | 263.90% | 273.05% | |
Share Based Compensation of Revenue |
27.57% | 26.72% | 24.47% | 26.22% | |
Interest Coverage |
— | (33.98) | (51.22) | — | |
Operating CF/Net income |
0.00 | 0.91 | 0.88 | 1.00 | |
Depreciation/Fixed assets |
0.00 | (1.01) | (1.34) | (1.69) | |
Capex/Depreciation |
— | 0.00 | 0.00 | 3.78 | |
Revenue per Share |
1.23 | 1.18 | 1.00 | 0.86 | |
Operating CF per Share |
(1.84) | (1.98) | (1.76) | (1.73) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.16) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.19 |
Columns are period end dates · fundamentals updated 5 Nov 2026